drugset / Trial / NCT00905138

First-in-Human Single Ascending and Multiple Dose of GLPG0259

NCT00905138

Phase 1 Completed 32 enrolled Lakefront Biotherapeutics NV
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral dose of GLPG0259 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0259 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Timeline

Start
2009-03
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG0259 Small molecule Oral

Indications

No indication recorded.